|
NAA35 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.11457542984317E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
9.36819954944212E-10 |
| Normal-vs-Stage2 |
1.19229999995252E-06 |
| Normal-vs-Stage3 |
2.84740009348639E-10 |
| Normal-vs-Stage4 |
2.80809819841465E-11 |
| Stage1-vs-Stage2 |
5.274600E-01 |
| Stage1-vs-Stage3 |
1.585370E-01 |
| Stage1-vs-Stage4 |
4.438700E-03 |
| Stage2-vs-Stage3 |
7.200600E-01 |
| Stage2-vs-Stage4 |
1.665980E-01 |
| Stage3-vs-Stage4 |
2.052200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.30848673510309E-12 |
| Normal-vs-AfricanAmerican |
2.536900E-03 |
| Normal-vs-Asian |
4.14880000021434E-07 |
| Caucasian-vs-AfricanAmerican |
2.572200E-01 |
| Caucasian-vs-Asian |
8.326800E-01 |
| AfricanAmerican-vs-Asian |
3.990600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.01021446552841E-12 |
| Normal-vs-Female |
1.68430047686741E-10 |
| Male-vs-Female |
1.655640E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.86939999433389E-09 |
| Normal-vs-Age(41-60Yrs) |
1.55309987093233E-10 |
| Normal-vs-Age(61-80Yrs) |
7.03070046625953E-10 |
| Normal-vs-Age(81-100Yrs) |
9.976700E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.553800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.122800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.156800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.240400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.420200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.006400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.136210E-01 |
| Classical-VS-Follicular |
9.382200E-01 |
| Classical-VS-Other |
2.536400E-01 |
| Classical-VS-Normal |
6.52400355960481E-11 |
| Tall-VS-Follicular |
1.632630E-01 |
| Tall-VS-Other |
7.209000E-01 |
| Tall-VS-Normal |
1.82170000195825E-08 |
| Follicular-VS-Other |
3.942200E-01 |
| Follicular-VS-Normal |
2.33849999997648E-06 |
| Other-VS-Normal |
1.420520E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.54890000825247E-09 |
| Normal-vs-N1 |
4.40600000928271E-09 |
| N0-vs-N1 |
1.192580E-01 |
|
|
